健民集团前三季度净利2.86亿元，同比下降11.16%

Core Insights - The company reported a revenue of 2.552 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 11.43% [1] - The net profit attributable to shareholders was 286 million yuan, down 11.16% year-on-year [1] Revenue Breakdown - The pharmaceutical manufacturing segment experienced a revenue increase of 19.67% year-on-year, driven by growth in the company's leading and new products [1] - Conversely, the pharmaceutical commercial segment saw a significant revenue decline of 36.91%, attributed to the company's ongoing optimization of its commercial subsidiaries and the gradual reduction of low-margin and inefficient businesses [1] Profit Analysis - The decrease in net profit was primarily due to reduced investment income from joint ventures and a decline in non-recurring gains and losses [1]